TWIST2 Antibody

Code CSB-PA848823DSR1HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human kidney tissue using CSB-PA848823DSR1HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human liver tissue using CSB-PA848823DSR1HU at dilution of 1:100

  • Immunofluorescent analysis of Hela cells using CSB-PA848823DSR1HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) TWIST2 Polyclonal antibody
Uniprot No.
Target Names
TWIST2
Alternative Names
bHLHa39 antibody; Class A basic helix-loop-helix protein 39 antibody; Dermis expressed protein 1 antibody; Dermis-expressed protein 1 antibody; DERMO 1 antibody; Dermo-1 antibody; DERMO1 antibody; MGC117334 antibody; Twist 2 antibody; Twist homolog 2 (Drosophila) antibody; Twist homolog 2 antibody; Twist related bHLH protein Dermo1 antibody; Twist related protein 2 antibody; Twist-related protein 2 antibody; Twist2 antibody; TWST2_HUMAN antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Twist-related protein 2 protein (1-70AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Polyclonal
Isotype
IgG
Purification Method
Antigen Affinity Purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Form
Liquid
Tested Applications
ELISA, IHC, IF
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Binds to the E-box consensus sequence 5'-CANNTG-3' as a heterodimer and inhibits transcriptional activation by MYOD1, MYOG, MEF2A and MEF2C. Also represses expression of proinflammatory cytokines such as TNFA and IL1B. Involved in postnatal glycogen storage and energy metabolism. Inhibits the premature or ectopic differentiation of preosteoblast cells during osteogenesis, possibly by changing the internal signal transduction response of osteoblasts to external growth factors.
Gene References into Functions
  1. Together, these data suggest that the S18-2 protein induces epithelial to mesenchymal cell transition through the TWIST2/E-cadherin signalling and, consequently, CXCR4-mediated migration of prostate cancer cells. PMID: 29396484
  2. TWIST2 induces miR-221-3p expression and consequently suppresses its direct target, THBS2, in lymphatic metastasis cervical cancer. PMID: 29242498
  3. epithelial membrane protein 3 is a downstream effector of TWIST1/2 in inducing epithelial-to-mesenchymal transition in gastric cancer. Epithelial membrane protein 3 upregulation might be associated with gastric cancer metastasis and is a potential indicator of unfavorable overall survival and progression-free survival in gastric cancer patients PMID: 28718375
  4. Findings indicated that HIF-2alpha promotes epithelial-mesenchymal transition in pancreatic cancer by regulating Twist2 binding to the promoter of E-cadherin. PMID: 26842802
  5. A homozygous missense mutation in the TWIST2 gene was described in 3 siblings affected by Setleis syndrome. An alteration of bHLH domain, and loss of transcription factor's function was predicted due to protein substitution. PMID: 25410422
  6. TWIST2 regulates epithelial-mesenchymal transition by depriving the epithelial cell phenotype of E-cadherin and endowing the mesenchymal cell phenotype with Vimentin, which may be involved in the progression and prognosis of ovarian cancer. PMID: 27048119
  7. MACC1 promotes vasculogenic mimicry in gastric cancer by regulating the HGF/c-Met-TWIST1/2 signaling pathway. PMID: 25895023
  8. In patients with no duplication/triplication of the 1p36.22p36.21 region and no mutations in TWIST2, there are mutation(s) in one of the 30 genes in this region or mutations in other as yet unidentified genes at different locations PMID: 25728400
  9. Data suggest that TWIST1 and to a lesser degree TWIST2 expressed within the tumor stroma could contribute to the epithelial-mesenchymal transition (EMT)-like tumor budding phenotype in colorectal cancers. PMID: 25528769
  10. A substituted lysine at TWIST2 residue 75 results in Ablepharon Macrostomia Syndrome, whereas a glutamine or alanine yields Barber-Say Syndrome. PMID: 26119818
  11. Results show that Twist2 expression was gradually increased during the progression from normal cervical squamous epithelium to cervical intraepithelial neoplasia (CIN) and cervical squamous cell carcinoma. PMID: 25420506
  12. Data have identified a novel TWIST2-p21 axis that regulates the cell cycle of both normal and leukemic hematopoietic cells, which implicates TWIST2 as a novel tumor suppressor in human acute myeloid leukemia. PMID: 25088197
  13. TWIST1 and TWIST2 are expressed in skeletal muscle and remained unaltered in metabolic diseases. PMID: 25663706
  14. Twist2 plays roles in osteogenesis differentiation, tumor formation and epithelial-mesenchymal transition.[review] PMID: 25608809
  15. LPS promotes PDCD4 degradation via a pathway involving PI3K and mTOR, releasing Twist2, which induces IL-10 via c-Maf. PMID: 24982420
  16. Twist2 is the key Twist isoform coupling aberrant signals from pithelial-mesenchymal transition (EMT) to senescence and is an important candidate biomarker for cervical cancer prognosis. PMID: 24974259
  17. nuclear beta-catenin is accumulated in Twist2-induced EMT cells to facilitates ovarian cancer invasion and metastasis. PMID: 24244294
  18. These data highlight a pivotal role for miR-138 in the regulation of colorectal cancer metastasis by targeting TWIST2. PMID: 24171926
  19. Data indicate that the expression of Twist2 and Runx2 differs significantly in mesenchymal stromal cells from bone marrow (bmMSC) compared to MSC from term placenta (pMSC). PMID: 23763516
  20. identification of the Twist2-CD24 signaling pathway provides a potential therapeutic approach to target cancer stem cells in HCCs PMID: 24193512
  21. heterogeneous expression of Twist2 in breast tumors may have a functional link to tumor progression PMID: 23133563
  22. Elevated expression of TWIST2 can contribute to invasion and metastasis of adenoid cystic carcinoma (ACC), and there might be some correlation between the hypoxia microenvironment and epithelial-mesenchymal transition in ACC. PMID: 22103974
  23. This study suggests a dual role for epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia, initially through altering cell growth and survival properties and subsequently by increasing resistance to chemotherapy. PMID: 22058208
  24. upregulation of TWIST2, correlated with poor differentiation grade and shorter survival and identifies a subset of node-positive oral cavity/pharynx cancer patients with very poor prognosis PMID: 22201613
  25. Twist1 and Twist2 modulate ATF4-dependent transcriptional activity in response to Parathyroid hormone. PMID: 21866569
  26. Mexican-Nahua sibs with facial and ophthalmologic features of FFDD type III were evaluated. Genomic DNAs were isolated for sequencing of the TWIST2 gene. The affected sibs were homozygous for a novel TWIST2 frameshift mutation, c.168delC (p.S57AfsX45). PMID: 21931173
  27. TWIST2 overexpression was linked to cervix cancer progression, which makes it a promising marker for determining the metastatic potential. PMID: 22018873
  28. overexpression of Twist2 may contribute to breast cancer progression by activating the epithelial to mesenchymal transition programme and enhancing the self-renewal of cancer stem-like cells. PMID: 21602879
  29. these data suggest that the C-terminal domain of TWIST2, which is missing in the Q119X mutant form of TWIST2, is responsible for proper transactivation of the periostin gene. PMID: 21801849
  30. Study correlates reduced TWIST2 and OPG expression with increased osteocalcin levels, thereby linking altered bone remodeling to energy homeostasis in hereditary HGPS. PMID: 21738662
  31. Our data implicate dermo1 as a tumor suppressor gene and a valuable molecular marker for human cancer PMID: 21109964
  32. TWIST2 recessive mutations cause an focal facial dermal dysplasias and dominant TWIST1 mutations cause Saethre-Chotzen craniocynostosis suggests that they function independently in skin and bone development. PMID: 20691403
  33. increased expression in T-cell is associated with resistance to apoptosis and tumor progression PMID: 19937140
  34. Epigenetic silencing of TWIST2 in mutated Ig V(H)is associated with chronic lymphocytic leukemia PMID: 15809452
  35. findings suggest that reduced expression of TWIST suppresses the multistep process of peritoneal dissemination (detachment from the primary lesion, adhesion to MCs and invasion of MCs). PMID: 17487558
  36. Twist proteins promote malignant conversion and metastatic dissemination. PMID: 18598946
  37. hypoxic TWIST1 induction is regulated by both HIF-1 and HIF-2 proteins through distinct regulatory elements in a tissue-specific manner PMID: 19644484

Show More

Hide All

Involvement in disease
Focal facial dermal dysplasia 3, Setleis type (FFDD3); Ablepharon-macrostomia syndrome (AMS); Barber-Say syndrome (BBRSAY)
Subcellular Location
Nucleus. Cytoplasm. Note=Mainly nuclear during embryonic development. Cytoplasmic in adult tissues.
Tissue Specificity
In the embryo, highly expressed in chondrogenic cells. In embryonic skin, expressed in the undifferentiated mesenchymal layer beneath the epidermis which later develops into the dermis. Expressed in early myeloid cells but not in lymphoid cells in the liv
Database Links

HGNC: 20670

OMIM: 200110

KEGG: hsa:117581

STRING: 9606.ENSP00000405176

UniGene: Hs.422585

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*